

<https://www.aphadruginfoline.com>)

[Home](#) > FDA approves longer-acting calaspargase pegol-mknl for ALL

---

Generic Name:

Calaspargase pegol-mknl

Trade Name:

Asparlas

Company:

Servier Pharmaceuticals

Notes:

[FDA approved](#) calaspargase pegol-mknl, an asparagine-specific enzyme, as a component of a multiagent chemotherapeutic regimen for acute lymphoblastic leukemia (ALL) in pediatric and young adult patients aged 1 month to 21 years. This new product provides for a longer interval between doses compared with other available pegaspargase products.

Approval was based on a demonstration of the achievement and maintenance of nadir serum asparaginase activity above the level of 0.1 U/mL when using calaspargase pegol-mknl, 2,500 U/m<sup>2</sup> intravenously, every 3 weeks. The pharmacokinetics of calaspargase pegol-mknl were studied when administered in combination with multiagent chemotherapy in 124 patients with B-cell lineage ALL.

The most common adverse reactions were elevated transaminase, increased bilirubin, pancreatitis, and abnormal clotting studies. In a randomized trial, the safety profile of calaspargase pegol-mknl administered every 3 weeks was similar to that of pegaspargase administered every 2 weeks.

The recommended calaspargase pegol-mknl dose is 2,500 units/m<sup>2</sup> intravenously, administered at a minimum dosing interval of every 21 days.

Medication Monitor Categories:

[New Drug Approvals](#)

---

**Source URL:** <https://www.aphadruginfoline.com/new-drug-approvals/fda-approves-longer-acting-calaspargase-pegol-mknl-all>